NTLA FY2027 EPS Estimate Cut by Brookline Capital Management

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Management dropped their FY2027 EPS estimates for Intellia Therapeutics in a research note issued to investors on Thursday, November 7th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $21.07 for the year, down from their previous estimate of $22.05. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.21) per share.

Other equities research analysts also recently issued research reports about the company. Oppenheimer cut their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday. Chardan Capital decreased their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, Citigroup reduced their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.33.

Intellia Therapeutics Trading Up 4.6 %

Intellia Therapeutics stock opened at $17.50 on Monday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -3.22 and a beta of 1.81. The stock’s fifty day simple moving average is $19.17 and its 200-day simple moving average is $22.23. Intellia Therapeutics has a twelve month low of $13.95 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.38) earnings per share.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently made changes to their positions in NTLA. Blue Trust Inc. raised its stake in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $41,000. Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $54,000. Finally, First Horizon Advisors Inc. grew its position in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after buying an additional 472 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.